New Antibiotic to Treat Pediatric Patients With Infections Due to a Specific Bacteria (Vancomycin-Resistant Enterococcus)
New Antibiotic to Treat Pediatric Patients With Infections Due to a Specific Bacteria (Vancomycin-Resistant Enterococcus)
This study will treat pediatric patients who have infections that are due to a specific
 bacteria (Vancomycin-Resistant Enterococcus)
Other specific inclusion/exclusion criteria may apply. In order to determine eligibility,
 further examination by the investigator is necessary.

 Inclusion Criteria:

 -  Hospitalized/chronic care pediatric patients (birth through 17 years)

 -  Known infections due to vancomycin-resistant enterococcus species, including diagnosis
 of hospital-acquired pneumonia, complicated skin and skin structure infections,
 catheter-related bacteremia, bacteremia of unidentified source, and other infections

 -  Requires a minimum of 3 days of IV medication

 -  Patients with mixed infections due to VRE & gram negative bacteria are allowed to
 enroll in the study. For most of the infections, 2 or more of additional symptoms are
 required.

 Exclusion Criteria:

 -  Potentially effective concomitant antibiotic

 -  A high surgical cure rate

 -  Medical conditions which would preclude clinical evaluation or require treatment of
 longer duration than 28 days

 -  24 hours of antibiotic treatment within 48 hours of study entry (unless pre-approved)

 -  Having an infected device that could not be removed